Literature DB >> 508594

8-MOP plasma levels in PUVA problem cases with psoriasis.

G Wagner, C Hofmann, U Busch, J Schmid, G Plewig.   

Abstract

8-MOP plasma levels of psoriatic patients poorly responsive to PUVA treatment (PUVA problem cases) (N = 14) and of psoriatic patients with adequate response to photochemotherapy (N = 7) were measured for 8 h after oral ingestion of 0.6-0.8 mg/kg body weight, using a gas chromatographic method. We investigated whether there are any differences in the course of the plasma kinetics between the two groups. Problem patients showed significantly lower 8-MOP plasma levels than the control group. Furthermore, the 8-MOP plasma levels increased more rapidly in the control group than in these problem patients. Deviations in time of the maximum 8-MOP plasma levels from the expected 2 h peak could be observed in 50% of the problem cases compared to only 14% of the control patients. There is no correlation between the dose and the 8-MOP plasma level achieved in the two groups, i.e. higher doses do not result in high levels. In individual cases there is not always a correlation between the plasma maximum of 8-MOP at the time of UV-A irradiation and the response to treatment. Adjustment of the UV-A irradiation to coincide with the maximum plasma levels led to an improvement in therapeutic results for three problem patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508594     DOI: 10.1111/j.1365-2133.1979.tb05621.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.

Authors:  A H Siddiqui; L Stolk; H R Korthals Altes-Levij van Vinninghe; A Kammeijer; R H Cormane
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

2.  Intraindividual variations of 8-methoxypsoralen plasma levels.

Authors:  M Schäfer-Korting; H C Korting
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

3.  Determination of 8-methoxypsoralen levels in plasma and skin suction blister fluid by a new sensitive fluorodensitometric method.

Authors:  H C Korting; M Schäfer-Korting; E Roser-Maass; E Mutschler
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

Review 4.  5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

5.  Variations in skin photosensitization during repeated oral 8-methoxypsoralen medication.

Authors:  C T Jansén; G Wilén; R Paul
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

Review 6.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Food-induced increase in bioavailability of 5-methoxypsoralen.

Authors:  H Ehrsson; I Wallin; A M Ros; S Eksborg; M Berg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid.

Authors:  J Lauharanta; T Juvakoski; L Kanerva; A Lassus
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.